In this special episode of #IndustryInsights, we spoke with Dr. Saskia De Man, Dr. Marrit Putker, and Dr. Pirouz Daftarian from Crown Bioscience. Saskia, Marrit, and Pirouz discuss the impact of T cell-directed immunotherapy on the cancer-immunity cycle. In particular, the speakers address the application of cytokine analysis, high-content imaging, tumor organoids, 3D ex vivo microtumors, FACS, and high-throughput assays to evaluate T-cell based immuno-oncology therapies. They also provide an overview of models and assays available for commonly researched cancer indications, discuss the advantages of using allogeneic vs. autologous immune cells and dysfunctional T cells for testing IO drugs.

To watch our recent webinar, Targeting T Cells Within the Cancer Immunity Cycle, click here.
To read our recent blog article, “The Cancer-Immunity Cycle: Research Solutions for Preclinical Immuno-Oncology”, click here.

To watch the interview, click here.